동향
전체 8345
  • Developing Treatment for Hereditary Neuromuscular Disease
    • - Kenneth Fischbeck, M.D., National Institute of Neurological Disorders and Stroke, NIH (2011/11/04)
    • - Category : Wednesday Afternoon Lectures
    Several thousand human disease genes have been identified over the past 25 years. The challenge now is to convert what we know about the causes and mechanisms of hereditary diseases into safe and effective treatment. We are finally close to doing this for two pediatric neuromuscular diseases, Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA).

    DMD is characterized by progressive weakness due to muscle degeneration. The disease is caused by mutations in the muscle protein dystrophin. Most of the mutations are partial gene deletions that shift the translational reading frame of the mRNA, leading to a truncated and unstable protein. Approaches to treatment include enhancing muscle regeneration and replacing or correcting the gene at the DNA or mRNA level. Myostatin inhibition and drugs that promote read-through of mutations have shown benefit in animals but not yet in clinical trials. Gene replacement has low efficiency and may induce an immune response to dystrophin. Oligonucleotide therapy to induce exon skipping may be the most promising approach at present. The oligonucleotides target specific mutations at the mRNA level. Recent clinical studies have shown partial restoration of muscle dystrophin with local and systemic delivery, and international trials are in progress.

    SMA is the most common severe hereditary disease of infancy. It is characterized by weakness of the extremity and respiratory muscles due to motor neuron loss. SMA is caused by mutations that lead to reduced levels of the survival motor neuron (SMN) protein, which is an important factor in mRNA splicing. Motor neurons may be particularly vulnerable to SMN deficiency because of their unusual structure and function. A variety of cell and animal models are available to test potential SMA treatments. Histone deacetylase inhibitors are beneficial in mice, and this effect can be enhanced by improved nutrition. Clinical trials of drugs that increase SMN have had mixed results to date, and assays to screen for better drugs have been developed. Oligonucleotide and gene replacement therapy have recently shown great promise in animal studies, and clinical trials are planned. Meanwhile, there is evidence that better respiratory and nutritional support can be very helpful. Thus, the clinical outcome may be improved by optimizing currently available treatment.

    The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide.

    For more information, visit:
    The NIH Directors Wednesday Afternoon Lecture Series

    Developing Treatment for Hereditary Neuromuscular Disease

  • Research with Children; Undue Inducement/Informed Consent; Participant Panel (Course 5)
    • - Robert Nelson, MD PhD; Neal Dickert, MD PhD; Christine Grady, RN PhD (2011/11/03)
    • - Category : Bioethics
    Ethical and Regulatory Aspects of Clinical Research

    Research with Children; Undue Inducement/Informed Consent; Participant Panel (Course 5)

  • Scientific Management Review Board - October 2011
    • - NIH Office of the Director (2011/11/03)
    • - Category : Scientific Management Review Board
    Scientific Management Review Board

    For more information, visit: http://smrb.od.nih.gov

    Scientific Management Review Board - October 2011

  • ASA All Hands Meeting - October 2011 (HHS Only)
    • - HHS (2011/11/03)
    • - Category : HHS Only
    The ASA All Hands meeting is designed to provide the ASA and other office heads the platform to provide information, share accomplishments, best practices and lesson learned to the employees that fall under the ASA banner

    For more information, visit: http://www.hhs.gov/asa

    ASA All Hands Meeting - October 2011 (HHS Only)

  • 27th International Neurotoxicology Conference - October 2011
    • - NIH (2011/11/03)
    • - Category : Conferences
    Environmentally Triggered Neurodevelopmental Disorders Focus on Endocrine Disruption and Sex Differences in Autism, ADHD, and Schizophrenia

    27th International Neurotoxicology Conference - October 2011

  • More Than Words - NIH Celebrates Accessibility
    • - Stacy Charland, Andrea Norris, Lawrence Tabak, Teresa Shea, Mike Paciello, Bruce Bailey, Mat McCollough, Angela Hooker, Jonathan Lazar, Kim Kirkpatrick and Joel Snyder (2011/11/03)
    • - Category : Conferences
    Please join us for, ???More Than Words - NIH Celebrates Accessibility!???

    This program will serve as the capstone event to NIH???s month long celebration of National Disability Employment Awareness Month.

    At NIH, our commitment to accessibility is more than just words. Our commitment to accessibility is an essential component of how we can achieve our mission and subsequently, provide better health information for everyone. NIH welcomes all participants, from our federal colleagues to industry representatives, for an event that will challenge and inform as we celebrate accessibility.

    Dr. Lawrence A. Tabak, NIH Deputy Director will provide opening remarks. A keynote address, Q&A panel and interactive demonstration will be delivered by outstanding leaders in the field of accessibility. Plan to participate in the Q&A panel by sending your questions to NIHMoreThanWords@mail.nih.gov
    on or prior to the day of the event.

    The full agenda is available here: http://ocio.od.nih.gov/morethanwords/agenda.html

    Over 20 exhibitors including federal colleagues and industry leaders like Adobe, Apple, Google, HiSoftware, Microsoft and more will be in the Natcher Atrium from 8:30 am to 4:00 pm to share information, give demonstrations and take questions.

    This event is sponsored by:
    NIH OD Office of the Chief Information Officer (OCIO), NIH Section 508 Advisory Group, NIH Office of Equal Opportunity and Diversity Management (OEODM), Disability Program Manager, and the Center for Information Technology (CIT), NIH

    More Than Words - NIH Celebrates Accessibility

  • Cerebellar Learning: Beyond the Purkinje Cell
    • - Sascha du Lac, PhD, Salk Institute for Biological Studies (2011/11/03)
    • - Category : Neuroscience
    Neuroscience Seminar Series

    Dr. Sascha du Lacs research is focused on the neural mechanisms of learning. They use motor learning in eye movements as a model system to examine how cellular and molecular mechanisms of plasticity operate in the context of neural circuits to improve behavioral performance. Their laboratory employs a variety of techniques to identify mechanisms by which the cerebellum controls motor learning, including behavioral analyses of eye movements in transgenic mice and cellular physiological studies in brain slices. They study learning in a well-defined behavior, the vestibulo-ocular reflex (VOR), which enables clear vision during head movements. Learning in the VOR occurs whenever vision is compromised persistently during head movements. The neural circuitry for the VOR is well understood, enabling us to link specific cellular and molecular mechanisms with their consequences for learning. Their lab studies how changes in intrinsic neuronal excitability and synaptic transmission operate within the circuit for the VOR to transform experience into adaptive changes in behavior.

    Cerebellar Learning: Beyond the Purkinje Cell

  • Nuclear Contacts and Targeted DNA Breaks Regulate the Frequency of B Cell Chromosomal Translocations
    • - Rafael Casellas, Ph.D. - NIH Directors Seminar Series (2011/11/02)
    • - Category : NIH Directors Seminars
    NIH Directors Seminar Series

    For more information, visit: http://www.nih.gov/about/director/dirsem.htm

    Nuclear Contacts and Targeted DNA Breaks Regulate the Frequency of B Cell Chromosomal Translocations

  • TRACO: Ovarian cancer: Genomics
    • - Christine Annunziata, Javed Khan (2011/11/02)
    • - Category : TRACO
    The Translational Research in Clinical Oncology (TRACO) course will be held on Monday afternoons from September to December at the Bethesda campus, Bldg. 50 ground floor auditorium. TRACO is designed to provide an overview of general principles of cancer biology and treatment, epidemiology, mechanisms of resistance, metastasis, use of preclinical models, and identification of novel molecular targets. Participants will have an unprecedented opportunity to learn new information, glimpse into future developments of translational research in clinical oncology, meet leaders in cancer research, and interview cancer survivors. These courses are part of a curriculum for training NCI clinical and postdoctoral fellows.

    For more information, visit: http://ccr.cancer.gov/careers/courses/traco

    TRACO: Ovarian cancer: Genomics

  • Medicine Dish: Medicare Part D and Program Updates
    • - Kitty Marx, Tribal Affairs Group, CMS (2011/11/01)
    • - Category : CMS - Centers for Medicare & Medicaid Services
    Experts from IHS and CMS discuss Medicare Part D and recent Medicare program changes. Topics include: new dates for Open Enrollment; creditable coverage letters; plan changes for 2011; LIS, redeeming and reassignment; Medicare Plan Enrollment; Medicare program updates and a demonstration of the updated Medicare Plan Finder on www.medicare.gov.

    Presenters: Indian Health Service ??? Pamela Schweitzer; CMS ??? Kay Pokrzywa, Roslyn Thomas, Stacey Platte, David Nolley, Kitty Marx

    Medicine Dish: Medicare Part D and Program Updates

  • Expanding Roles for Memory CD4 T Cells in Anti-Viral Responses
    • - Dr. Susan Swain (2011/11/01)
    • - Category : Immunology
    Immunology Interest Group Seminar

    Expanding Roles for Memory CD4 T Cells in Anti-Viral Responses

  • NIH-Supported International Collaborations: Changes for Issuing FY 2012 Awards (HHS Only)
    • - James Onken, Jim Herrington and Rebecca Claycamp (2011/11/01)
    • - Category : ESA (HHS Only)
    To support NIH initiatives in global health research and solve long-standing issues in NIH???s ability to track our international collaborations, several changes are required in the issuance of FY 2012 grant awards. These changes affect program and grants management staff eRA checklists and information collection through the NIH Foreign Tracking System. This one-hour training session will provide:
    • Background on the need for these changes

    • Long-term changes underway in NIH data management systems, and short-term changes for issuing FY 2012 awards

    • New checklist items for both program and grants management staff

    • New policies and procedures for the collection of information on FY 2012 awards through the NIH Foreign Tracking System


    For more information, visit: http://odoerdb2.od.nih.gov/oer/training/esa/esa_training_20111027.htm

    NIH-Supported International Collaborations: Changes for Issuing FY 2012 Awards (HHS Only)

  • CSR SRO Advisory Council Meeting - October 2011 (NIH Only)
    • - Dr. Larry Tabak (2011/10/30)
    • - Category : NIH Only
    Mandatory Bi- Annual meeting to review evaluate CSR Functions

    For more information, visit: https://webmeeting.nih.gov/csrsroadvisorymeeting2011/

    CSR SRO Advisory Council Meeting - October 2011 (NIH Only)

  • OHR Brown Bag Seminar - October 2011 (NIH Only)
    • - Dr. Jim Bjork & Dr. Gene Major (2011/10/30)
    • - Category : NIH Only
    OHR Professional development and training

    OHR Brown Bag Seminar - October 2011 (NIH Only)

  • 2011 Anita B. Roberts Lecture: Chromatin Regulation of Innate Immunity
    • - Keiko Ozato, Ph.D. (2011/10/30)
    • - Category : Anita B. Roberts
    Dr. Keiko Ozato will give the 11th lecture in the Anita B. Roberts lecture series, which highlights outstanding research achievements of women scientists in the Intramural Research Program.

    The Anita B. Roberts Lecture Series, Distinguished Women Scientists at NIH, highlights outstanding research achievements of women scientists at the NIH. The seminar is dedicated to Dr. Anita Roberts and honors her role as an exceptional mentor and scientist.

    Anita joined the NIH in 1976 and spent 30 years at NCI, rising to Chief of the Laboratory of Cell Regulation and Carcinogenesis. She died of gastric cancer in May 2006, leaving a legacy that touched both the professional and personal lives of all who knew her. Her work focused primarily on TGF-beta and its role in the growth of epithelial and lymphoid cells. In 2003, Thomas Scientifics Science Watch listed her among the 50 most-cited scientists during 1982 to 2002, a feature called Twenty Years of Citation Superstars.

    Anita was a superstar to many for her mentoring talent and her ability to balance family and work life. Her successful lab was well known for meeting family needs and for providing an environment both intellectually and emotionally enriching. The lecture series in her name serves to highlight the fact that the NIH recognizes the value and necessity of a supportive workplace.

    For more information, visit: http://sigs.nih.gov/wsa/Pages/Archives.aspx

    2011 Anita B. Roberts Lecture: Chromatin Regulation of Innate Immunity

  • Preventing Injuries with Good Housekeeping (NIH Only)
    • - NIH DOHS (2011/10/28)
    • - Category : Occupational Health & Safety Lectures (NIH Only)
    Occupational Health & Safety Lecture

    Learn about Preventing Injuries with Good Housekeeping and Using Ladders Safely.

    Preventing Injuries with Good Housekeeping (NIH Only)

  • Quality Data for Pediatric Clinical Trials
    • - NCRR CTSA Program and NICHD (2011/10/28)
    • - Category : Conferences
    The CTSA Consortium Child Health Oversight Committee and the Eunice Kennedy Shriver National Institute for Child Health and Human Development will jointly sponsor a meeting featuring national leaders in pediatric therapeutic development. FDA Deputy Commissioner for Medical Products and Tobacco, Dr. Stephen Spielberg, will be the keynote speaker. A series of panels will cover the ethical and regulatory framework of pediatric research, informatics challenges with the management of pediatric trial data, and considerations unique to multi-site clinical trials. Panelists and discussants will include representative from FDA, academia/AHCs, pharmaceutical and medical device firms, clinical research consultants, and contract research organizations.

    For more information, visit: http://www.ctsaweb.org

    Quality Data for Pediatric Clinical Trials

  • TRACO: Cancer stem cells, Epidemiology
    • - Karen Bussard: Neil Caporaso (2011/10/28)
    • - Category : TRACO
    The Translational Research in Clinical Oncology (TRACO) course will be held on Monday afternoons from September to December at the Bethesda campus, Bldg. 50 ground floor auditorium. TRACO is designed to provide an overview of general principles of cancer biology and treatment, epidemiology, mechanisms of resistance, metastasis, use of preclinical models, and identification of novel molecular targets. Participants will have an unprecedented opportunity to learn new information, glimpse into future developments of translational research in clinical oncology, meet leaders in cancer research, and interview cancer survivors. These courses are part of a curriculum for training NCI clinical and postdoctoral fellows.

    For more information, visit: http://ccr.cancer.gov/careers/courses/traco

    TRACO: Cancer stem cells, Epidemiology

  • Placebo Controlled Trials; Fair Subject Selection; Research with Pregnant Women (Course 4)
    • - Frank Miller, PhD; Dave Wendler, PhD, Maggie Little, PhD (2011/10/27)
    • - Category : Bioethics
    Ethical and Regulatory Aspects of Clinical Research

    Placebo Controlled Trials; Fair Subject Selection; Research with Pregnant Women (Course 4)

  • NIH Research Festival Opening Plenary Session: Molecular Mechanisms of Human Disease - 2011
    • - NIH Office of Intramural Research (2011/10/27)
    • - Category : Conferences
    Information provided from the Human Genome Project, as well as the rapid advancement of enabling molecular technologies, have provided a foundation for new approaches to unravel the mysteries of many diseases. In particular, genetic and genomic information is allowing unprecedented insights into the aberrant functions of overexpressed, repressed or dysregulated genes in many disease settings, and allowing researchers to interrogate and identify specific molecular mechanisms associated with disease causation and progression. These new insights into the molecular etiology of disease are now being rapidly exploited to provide new targets for development of new therapeutic and/or prevention strategies.

    For more information, visit: http://researchfestival.nih.gov

    NIH Research Festival Opening Plenary Session: Molecular Mechanisms of Human Disease - 2011